AK104 IV infusion；Chiauranib oral — Competitive Intelligence Brief

AK104 IV infusion；Chiauranib oral (AK104 IV infusion；Chiauranib oral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 1 Tyrosine kinase inhibitor VEGFR, PDGFR, FGFR Oncology Small molecule

Target snapshot

AK104 IV infusion；Chiauranib oral (AK104 IV infusion；Chiauranib oral) — Akeso. Tyrosine kinase inhibitor

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AK104 IV infusion；Chiauranib oral TARGET	AK104 IV infusion；Chiauranib oral	Akeso	phase 1	Tyrosine kinase inhibitor	VEGFR, PDGFR, FGFR
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
surufatinib + gemcitabine + nab-paclitaxel	surufatinib + gemcitabine + nab-paclitaxel	Tianjin Medical University Cancer Institute and Hospital	phase 3	Tyrosine kinase inhibitor	VEGFR, PDGFR, FGFR
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Vizimpro	Dacomitinib	Pfizer Inc.	marketed	Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

1. Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
2. Centre Leon Berard · 2 drugs in this class
3. AB Science · 2 drugs in this class
4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
5. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
6. Angion Biomedica Corp · 1 drug in this class
7. Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
8. Chang-Ming Huang, Prof. · 1 drug in this class
9. Deciphera Pharmaceuticals, LLC · 1 drug in this class
10. AstraZeneca · 1 drug in this class